Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALMS Alumis Inc.

交易中 05-27 10:42:40 EDT

21.81

-0.52

-2.33%

最高22.34	最低21.78	成交量14.92万
今开22.33	昨收22.33	日振幅2.51%
总市值27.74亿	流通市值16.68亿	总股本1.27亿
成交额329.18万	换手率0.20%	流通股本7,648万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":21.81,"timestamp":1779892955260,"preClose":22.33,"halted":0,"volume":149172,"delay":0,"changeRate":-0.023287057769816374,"floatShares":76484700,"shares":127199333,"eps":-1.8621956,"marketStatus":"交易中","change":-0.52,"latestTime":"05-27 10:42:40 EDT","open":22.33,"high":22.34,"low":21.78,"amount":3291827.154072,"amplitude":0.025078,"askPrice":21.83,"askSize":65,"bidPrice":21.71,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.8621956,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779912000000},"marketStatusCode":2,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":22.33,"preHourTrading":{"tag":"盘前","latestPrice":22.13,"preClose":22.33,"latestTime":"09:16 EDT","volume":114,"amount":2530.310028,"timestamp":1779887782467,"change":-0.2,"changeRate":-0.008957,"amplitude":0.023735},"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":22.33,"latestTime":"19:41 EDT","volume":27346,"amount":610541.9,"timestamp":1779838870567,"change":-0.33,"changeRate":-0.014778,"amplitude":0.014778},"volumeRatio":0.947526,"impliedVol":0.8743,"impliedVolPercentile":0.2231},"requestUrl":"/m/hq/s/ALMS","defaultTab":"news","newsList":[{"id":"1138091701","title":"Alumis旗下Envudeucitinib在两项三期试验中展现皮肤清除、生活质量及银屑病症状早期显著改善，凸显其作为斑块状银屑病一线口服疗法的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1138091701","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138091701?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:31","pubTimestamp":1774719072,"startTime":"0","endTime":"0","summary":"Alumis公司研发的Envudeucitinib在两项三期临床试验中取得突破性进展，该口服疗法在皮肤清除率、患者生活质量和银屑病核心症状方面均表现出早期且显著的改善效果。试验数据进一步验证了其作为斑块状银屑病前沿口服治疗方案的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199051063","title":"Alumis持续推进Envudeucitinib长期疗效与安全性评估：Onward3长期扩展试验进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=1199051063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199051063?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:30","pubTimestamp":1774719029,"startTime":"0","endTime":"0","summary":"Alumis Inc. 目前正通过Onward3长期扩展试验，持续评估其在研药物Envudeucitinib的长期疗效与安全性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197813725","title":"Alumis：Envudeucitinib展现强劲皮肤清除效果，两项试验中从第16周至第24周均实现高阈值临床应答","url":"https://stock-news.laohu8.com/highlight/detail?id=1197813725","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197813725?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:30","pubTimestamp":1774719011,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其研究药物Envudeucitinib在两项临床试验中表现出强大的皮肤清除能力。从治疗的第16周开始，直至第24周，该药物持续达到了高标准的临床应答阈值，显示出显著且持久的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144581026","title":"Alumis公布Envudeucitinib安全性数据：与二期项目一致，未出现新的安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1144581026","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144581026?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:30","pubTimestamp":1774719010,"startTime":"0","endTime":"0","summary":"Alumis Inc. 近日披露了Envudeucitinib的最新临床数据，显示该药物在安全性与耐受性方面表现良好，结果与二期临床试验项目的数据保持一致。研究中未观察到新的安全性信号，进一步支持了该疗法的开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104384434","title":"Alumis公布Envudeucitinib治疗中重度斑块型银屑病三期数据，将于2026年AAD年会作重磅报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1104384434","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104384434?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:04","pubTimestamp":1773835493,"startTime":"0","endTime":"0","summary":"生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。Alumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618919079","title":"Alumis Inc.盘中异动 股价大涨5.18%报28.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618919079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618919079?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:31","pubTimestamp":1773160311,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日00时31分，Alumis Inc.股票出现波动，股价快速拉升5.18%。截至发稿，该股报28.23美元/股，成交量44.3216万股，换手率0.36%，振幅7.28%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为1.60%。Alumis Inc.公司简介：Alumis Inc 是一家处于临床阶段的生物制药公司，专注于识别、收购并加速开发和商业化用于自身免疫性疾病的变革性药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031100315295474092&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031100315295474092&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172404239","title":"Form 4 | Alumis Inc.董事 Akkaraju Srinivas 增持588,235股","url":"https://stock-news.laohu8.com/highlight/detail?id=1172404239","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172404239?lang=zh_cn&edition=full","pubTime":"2026-01-14 07:25","pubTimestamp":1768346733,"startTime":"0","endTime":"0","summary":"Alumis Inc.的董事 Akkaraju Srinivas 于2026年1月9日通过 Samsara Opportunity Fund, L.P.增持了588,235股普通股，定价为每股$17。交易显示其对公司未来发展的信心，中长期来看可能带来积极影响。个人持股通过间接形式持有，目前总计持有1,853,488股，这一点值得投资者注意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Form 4 | Alumis Inc.董事 Akkaraju Srinivas 增持588,235股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603634859","title":"Alumis Inc.盘中异动 大幅上涨5.36%报22.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603634859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603634859?lang=zh_cn&edition=full","pubTime":"2026-01-14 00:11","pubTimestamp":1768320716,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日00时11分，Alumis Inc.股票出现异动，股价急速上涨5.36%。截至发稿，该股报22.22美元/股，成交量143.667万股，换手率1.15%，振幅8.97%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Alumis Inc.公司简介：Alumis Inc 是一家处于临床阶段的生物制药公司，专注于识别、收购并加速开发和商业化用于自身免疫性疾病的变革性药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114001156a4bf91be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114001156a4bf91be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1180282206","title":"ALUMIS INC.董事 Foresite Capital Management VI LLC 增持411,764股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180282206","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180282206?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:20","pubTimestamp":1768274427,"startTime":"0","endTime":"0","summary":"ALUMIS INC. 董事 Foresite Capital Management VI LLC 于2026年1月8日进行了2次增持，总计购买411,764股，每股价格为17美元。增持后其持股量增加，通常被视为利好信号，可能预示着公司未来发展前景良好，值得投资者关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181767663","title":"ALUMIS Inc.董事 James B. Tananbaum 增持411,764股","url":"https://stock-news.laohu8.com/highlight/detail?id=1181767663","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181767663?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:12","pubTimestamp":1768273933,"startTime":"0","endTime":"0","summary":"ALUMIS Inc. (ALMS) 董事 James B. Tananbaum 于2026年1月8日进行增持，购买了411,764股普通股票。此次增持每股价格为17美元。在购买后，James B. Tananbaum通过间接形式分别持有5,702,536股、2,908,332股、4,247,670股、194,459股、1,960,337股以及1,176,470股普通股票。董事的增持通常传递出对公司未来前景的信心，是一个利好信号，投资者可以关注公司后续表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ALUMIS Inc.董事 James B. Tananbaum 增持411,764股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107964214","title":"异动解读 | Alumis Inc.盘中大涨11.21%，因皮肤病药物临床试验成功及1.75亿美元股票发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1107964214","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107964214?lang=zh_cn&edition=full","pubTime":"2026-01-07 23:38","pubTimestamp":1767800321,"startTime":"0","endTime":"0","summary":"生物制药公司Alumis Inc.（ALMS）今日盘中大涨11.21%，股价表现强劲。消息面上，该公司的皮肤病药物envudeucitinib在两项后期研究中达到了主要目标，这增强了市场对其药物获批的信心。此外，公司宣布开始1.75亿美元的股票发行，计划将募集资金用于向美国FDA提交潜在的上市申请、envudeucitinib的上市准备工作以及其他临床开发项目。分析师普遍看好该股，所有8位分析师均给予正面评级，其中4位为“强烈买入”。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601815301","title":"美股异动 | 银屑病药物三期试验取得积极结果 Alumis(ALMS.US)开盘飙升超154%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601815301","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601815301?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:40","pubTimestamp":1767710453,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，Alumis开盘飙升超154%，创历史新高，报20.60美元。消息面上，该公司宣布了其envudeucitinib三期ONWARD1和ONWARD2临床试验的积极顶线结果。在这些试验中，Envudeucitinib在第16周的银屑病面积和严重程度指数75和静态医生整体评估0/1共同主要终点上，相对于安慰剂表现出更优的皮肤清除效果。在ONWARD1和ONWARD2中平均来看，74%的患者达到PASI 75，59%的患者达到sPGA 0/1，随着时间推移反应加深。此外，两个试验之间共同主要终点的安慰剂校正响应率保持一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174899077","title":"Alumis报告银屑病药物三期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174899077","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174899077?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:38","pubTimestamp":1767710300,"startTime":"0","endTime":"0","summary":"Alumis一度飙升近120%！报告银屑病药物三期临床试验取得积极结果。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Alumis报告银屑病药物三期临床试验取得积极结果","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154857920","title":"Alumis高管称Envudeucitinib与武田Zasocitinib相比\"极具竞争力\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1154857920","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154857920?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:34","pubTimestamp":1767706444,"startTime":"0","endTime":"0","summary":"在电话会议中，Alumis Inc.高管表示，公司坚信其研发的Envudeucitinib与武田制药的Zasocitinib相比具有显著竞争优势。该表态凸显了企业对自身产品疗效的信心，也预示着自身免疫疾病治疗领域可能迎来新的竞争格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165494801","title":"Alumis股价盘前飙升17.2%至9.74美元，公司皮肤病药物达成两项后期试验主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1165494801","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165494801?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:09","pubTimestamp":1767701353,"startTime":"0","endTime":"0","summary":"Alumis Inc. (ALMS) 股价在盘前交易中大幅上涨17.2%，报收于每股9.74美元。这一强劲表现源于公司宣布其研发的皮肤病药物在两项后期临床试验中，均已成功达到预设的主要研究终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185233710","title":"Alumis公司Envudeucitinib在III期临床项目中展现领先皮肤清除效果，领跑新一代口服斑块状银屑病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1185233710","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185233710?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:08","pubTimestamp":1767701322,"startTime":"0","endTime":"0","summary":"Alumis公司旗下药物Envudeucitinib在其III期临床项目中展现出卓越疗效，其皮肤清除效果在新一代口服斑块状银屑病疗法中处于领先地位。该药物在临床试验中表现出显著优势，为斑块状银屑病患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158074253","title":"Alumis公司Envudeucitinib展现与二期项目一致的良好安全性和耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1158074253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158074253?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:05","pubTimestamp":1767701105,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其候选药物Envudeucitinib在临床研究中展现出良好的安全性和耐受性特征，这一结果与二期临床试验项目的数据保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122336632","title":"Alumis公司Envudeucitinib治疗系统性红斑狼疮的Lumus 2B期试验顶线数据预计2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1122336632","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122336632?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:03","pubTimestamp":1767700994,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其用于治疗系统性红斑狼疮的在研药物Envudeucitinib，其名为Lumus的2B期临床试验的顶线结果，预计将于2026年第三季度揭晓。这一关键数据节点备受市场关注，将直接影响该药物的后续开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133830233","title":"Alumis Inc.遭遇里程碑付款违约：Climb Bio拒绝支付2026年1月1日到期的300万美元开发款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1133830233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133830233?lang=zh_cn&edition=full","pubTime":"2026-01-03 05:10","pubTimestamp":1767388215,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件披露，生物制药公司Alumis Inc.面临重大资金违约事件——其合作伙伴Climb Bio已正式拒绝支付原定于2026年1月1日到期的300万美元开发里程碑款项。这一突发状况不仅直接冲击了Alumis的现金流预期，更引发市场对双方战略合作可持续性的深度质疑。值得注意的是，该笔款项的拒付发生在关键药物研发阶段，可能预示着合作方对项目商业前景的重新评估。随着违约细节通过监管文件公之于众，投资者正密切关注事态发展对Alumis研发进度及财务健康的潜在连锁反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136452809","title":"Alumis Inc. 及其子公司向Climb Bio发出重大违约通知及索赔补偿申请——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1136452809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136452809?lang=zh_cn&edition=full","pubTime":"2026-01-03 05:09","pubTimestamp":1767388152,"startTime":"0","endTime":"0","summary":"根据一份提交至美国证券交易委员会（SEC）的文件显示，生物制药公司Alumis Inc.及其关联子公司已正式向Climb Bio公司发出通知，指控对方存在重大违约行为，并同时提出索赔补偿要求。此举标志着双方合作可能面临严重纠纷，引发市场对相关业务进展的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":0.0374},{"period":"1month","weight":-0.1043},{"period":"3month","weight":-0.2402},{"period":"6month","weight":1.9228},{"period":"1year","weight":3.5805},{"period":"ytd","weight":1.2879}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alumis Inc.于2021年1月29日注册成立，为特拉华州公司。他们是一家临床阶段的生物制药公司，最初专注于开发两种酪氨酸激酶2（TYK2）抑制剂：ESK-001，一种他们正在开发的第二代抑制剂，以实现最大的靶向抑制，以及A-005，一种中枢神经系统渗透分子。该公司的使命是通过靶向治疗取代广泛的免疫抑制，显著改善患者的生活。","exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}